Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial-Reference-Cited by-同舟云学术

Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial

Published:1998-09 Issue:5 Volume:82 Page:19L-24L
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Cohen Marc,Demers Christine,Gurfinkel Enrique P,Turpie Alexander G.G,Fromell Gregg J,Goodman Shaun,Langer Anatoly,Califf Robert M,Fox Keith A.A,Premmereur Jerome,Bigonzi Frederique

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCaulay KM, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE III, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable angina: diagnosis and management. Clinical practice guideline number 10 AHCPR Publication-No. 94-0602: Agency for health care policy and research, US Department of Health and Human Services. May 1994.

2. Aspirin, heparin, or both to treat acute unstable angina;Theroux;N Engl J Med,1988

3. Wallentin L for the RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827–830.

4. Combination antithrombotic therapy in rest unstable angina and non-q wave infarction in non-prior aspirin users;Cohen;Circulation,1993

5. Wallentin L for the Fragmin during instability in coronary artery disease (FRISC) Study Group. Low-molecular weight heparin during instability in coronary artery disease (FRISC) Study Group: low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561–568.

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Quantitative Bias Analysis to Assess Constancy Assumption in Noninferiority Trials Using Bayesian Hierarchical Models;Statistics in Biopharmaceutical Research;2022-06-30

2. Blood Constituents and Safety Pharmacology: In Vitro and In Vivo Thrombosis and Hemostasis Assays;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2022

3. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome;American Journal of Cardiovascular Drugs;2020-06-23

4. Comparison of RISK-PCI, GRACE, TIMI risk scores for prediction of major adverse cardiac events in patients with acute coronary syndrome;Croatian Medical Journal;2017-12

5. Critical Issues in Experimental Models;Drug Discovery and Evaluation: Pharmacological Assays;2016